Drugs that offer the potential to reduce hospitalization and mortality from SARS-CoV-2 infection: The possible role of the sigma-1 receptor and autophagy
- PMID: 34236922
- PMCID: PMC8290373
- DOI: 10.1080/14728222.2021.1952987
Drugs that offer the potential to reduce hospitalization and mortality from SARS-CoV-2 infection: The possible role of the sigma-1 receptor and autophagy
Abstract
Introduction: Despite the availability of new vaccines for SARS-CoV-2, there has been slow uptake and problems with supply in some parts of the world. Hence, there is still a necessity for drugs that can prevent hospitalization of patients and reduce the strain on health care systems. Drugs with sigma affinity potentially provide protection against the most severe symptoms of SARS-COV-2 and could prevent mortality via interactions with the sigma-1 receptor.Areas covered: This review examines the role of the sigma-1 receptor and autophagy in SARS-CoV-2 infections and how they may be linked. The authors reveal how sigma ligands may reduce the symptoms, complications, and deaths resulting from SARS-CoV-2 and offer insights on those patient cohorts that may benefit most from these drugs.Expert opinion: Drugs with sigma affinity potentially offer protection against the most severe symptoms of SARS-CoV-2 via interactions with the sigma-1 receptor. Agonists of the sigma-1 receptor may provide protection of the mitochondria, activate mitophagy to remove damaged and leaking mitochondria, prevent ER stress, manage calcium ion transport, and induce autophagy to prevent cell death in response to infection.
Keywords: COVID-19; SARS-CoV-2; autophagy; chlorpromazine; critical care; donepezil; fluoxetine; fluvoxamine; long COVID; sigma-1.
Figures
Similar articles
-
Sigma Receptor Ligands Prevent COVID Mortality In Vivo: Implications for Future Therapeutics.Int J Mol Sci. 2023 Oct 29;24(21):15718. doi: 10.3390/ijms242115718. Int J Mol Sci. 2023. PMID: 37958703 Free PMC article.
-
Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor.Eur Arch Psychiatry Clin Neurosci. 2021 Mar;271(2):249-258. doi: 10.1007/s00406-020-01231-x. Epub 2021 Jan 5. Eur Arch Psychiatry Clin Neurosci. 2021. PMID: 33403480 Free PMC article. Review.
-
[Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].Encephale. 2020 Jun;46(3S):S35-S39. doi: 10.1016/j.encep.2020.04.010. Epub 2020 Apr 29. Encephale. 2020. PMID: 32387014 Free PMC article. French.
-
Identification of antiviral antihistamines for COVID-19 repurposing.Biochem Biophys Res Commun. 2021 Jan 29;538:173-179. doi: 10.1016/j.bbrc.2020.11.095. Epub 2020 Dec 3. Biochem Biophys Res Commun. 2021. PMID: 33309272 Free PMC article.
-
Autophagy, Unfolded Protein Response, and Neuropilin-1 Cross-Talk in SARS-CoV-2 Infection: What Can Be Learned from Other Coronaviruses.Int J Mol Sci. 2021 Jun 1;22(11):5992. doi: 10.3390/ijms22115992. Int J Mol Sci. 2021. PMID: 34206057 Free PMC article. Review.
Cited by
-
Network analysis-guided drug repurposing strategies targeting LPAR receptor in the interplay of COVID, Alzheimer's, and diabetes.Sci Rep. 2024 Feb 21;14(1):4328. doi: 10.1038/s41598-024-55013-9. Sci Rep. 2024. PMID: 38383841 Free PMC article.
-
Fluvoxamine Exerts Sigma-1R to Rescue Autophagy via Pom121-Mediated Nucleocytoplasmic Transport of TFEB.Mol Neurobiol. 2024 Jan 5. doi: 10.1007/s12035-023-03885-9. Online ahead of print. Mol Neurobiol. 2024. PMID: 38180612
-
A conformational rearrangement of the SARS-CoV-2 host protein sigma-1 is required for antiviral activity: insights from a combined in-silico/in-vitro approach.Sci Rep. 2023 Aug 7;13(1):12798. doi: 10.1038/s41598-023-39662-w. Sci Rep. 2023. PMID: 37550340 Free PMC article.
-
Donepezil-associated survival benefits among Alzheimer's disease patients are retained but not enhanced during COVID-19 infections.Ther Adv Infect Dis. 2023 May 22;10:20499361231174289. doi: 10.1177/20499361231174289. eCollection 2023 Jan-Dec. Ther Adv Infect Dis. 2023. PMID: 37234745 Free PMC article.
-
Overview of the potential use of fluvoxamine for COVID-19 and long COVID.Discov Ment Health. 2023;3(1):9. doi: 10.1007/s44192-023-00036-3. Epub 2023 Mar 21. Discov Ment Health. 2023. PMID: 36968793 Free PMC article. Review.
References
-
- Dodds K, Broto VC, Detterbeck K, et al. The COVID-19 pandemic: territorial, political and governance dimensions of the crisis. Territory, Politics, Governance. 2020. May 26;8(3):289–298.
-
- Garg RK, Paliwal VK, Gupta A.. Encephalopathy in patients with COVID-19: a review. J Med Virol. 2021;93(1):206–222. - PubMed
-
- Taquet M, Geddes JR, Husain M, et al. 66-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8(5): 416–427. - PMC - PubMed
-
•• Indication of the need for treatment with neuroprotective drugs in COVID 19 patients.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
